SEC Form 10-K filed by Tango Therapeutics Inc.
$TNGX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/23/2026 | $19.00 | Outperform | Mizuho |
| 11/18/2025 | Peer Perform | Wolfe Research | |
| 8/19/2025 | $11.00 | Overweight | Piper Sandler |
| 7/17/2024 | $19.00 | Buy | Jefferies |
| 4/4/2024 | Overweight | Cantor Fitzgerald | |
| 2/12/2024 | $18.00 | Overweight | Piper Sandler |
| 12/8/2023 | $16.00 | Buy | B. Riley Securities |
| 10/20/2022 | $10.00 | Neutral → Buy | H.C. Wainwright |
S-8 - Tango Therapeutics, Inc. (0001819133) (Filer)
8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
10-K - Tango Therapeutics, Inc. (0001819133) (Filer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
Mizuho initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $19.00
Wolfe Research initiated coverage of Tango Therapeutics with a rating of Peer Perform
Piper Sandler initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $11.00
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Tango Therapeutics, Inc. (NASDAQ:TNGX, "Tango")) to evaluate Erasca's pan-RAS molecular glue, ERAS-0015, with Tango's PRMT5 inhibitor, vopimetostat (TNG462). "We've disclosed encoura
Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the n
BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call. Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston Corporate presentation on Wednesday, March 4 at 1:10-1:40 PM ETWebcast link here Barclays 28th Annual Global Healthcare Conference, Miami Hosting 1x1 meetings on Tuesday, March 10 2026 Leerink Partners Global Healthcare Conference, Miami Fireside chat
Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the n
Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company's founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Mr. Sung Lee to the Board of Directors. Mr. Lee has over 20 years of experience in finance leadership in the biopharmaceutical and technology industries. "We are delighted to welcome Sung Lee to our Board of Directors," said Barbara Weber, M.D., Chief Executive Officer of Tango Therapeutics. "Sung's proven track record in corporate strategy, investor relations and finance will be instrumental as we advance our lead program, vopimetostat, into reg
SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)
BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call. Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston Corporate presentation on Wednesday, March 4 at 1:10-1:40 PM ETWebcast link here Barclays 28th Annual Global Healthcare Conference, Miami Hosting 1x1 meetings on Tuesday, March 10 2026 Leerink Partners Global Healthcare Conference, Miami Fireside chat
BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cance
– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR and mPFS 9.1 months in histology agnostic cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity – – Company to hold conference call today at 8:30am ET – BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced positive data from its ongoing Phase 1/2 stud